{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:33:17Z","timestamp":1791304397902,"version":"4.3.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MAFLD\u2014previously termed NAFLD\u2014has emerged as the most common condition on a global scale. Obesity, insulin resistance, dyslipidemia, and atherosclerosis are closely linked to its pathogenesis. Lipid dysregulation, insulin resistance, and inflammatory status are reflected by the atherogenic index of plasma (AIP), computed as the logarithmic ratio of triglycerides to HDL-C. Although multiple studies have suggested an association between AIP and MAFLD\/NAFLD, the reported findings remain inconsistent. The present investigation sought to synthesize available evidence regarding the AIP\u2013MAFLD\/NAFLD relationship and to appraise the diagnostic accuracy of AIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 statement. PubMed, Embase, the Cochrane Library, and Web of Science were searched through October 2025. Fixed- or random-effects models were applied according to heterogeneity. Weighted mean difference (WMD) and pooled odds ratios (ORs) were calculated. Diagnostic performance was evaluated using a bivariate random-effects model to obtain pooled sensitivity, specificity, and summary receiver operating characteristic (SROC) curves. Subgroup analyses were performed by diagnostic criteria, age, diabetes status, BMI, and region. Meta-regression explored the influence of demographic and metabolic covariates. Sensitivity analyses and publication bias assessment using Egger regression and Deeks\u2019 asymmetry test were also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty observational studies involving 245,571 adults were included. AIP levels were significantly higher in MAFLD\/NAFLD patients than in controls (WMD\u00a0=\u00a00.26; 95% CI: 0.21\u20130.30). Elevated AIP was significantly associated with MAFLD\/NAFLD risk (pooled odds ratio = 3.18; 95% CI: 2.54\u20133.98). Subgroup analyses demonstrated greater consistency in studies using MAFLD diagnostic criteria and among obese populations. Diagnostic meta-analysis using a bivariate random-effects model yielded a pooled sensitivity of 0.73 and specificity of 0.65, with a summary AUC of 0.75 (95% CI: 0.71\u20130.79), indicating moderate diagnostic accuracy. Sensitivity analyses confirmed robustness, and no significant publication bias was detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated AIP is significantly associated with increased MAFLD\/NAFLD risk and shows moderate diagnostic performance. As a simple and cost-effective index derived from routine lipid profiles, AIP may serve as a useful early screening tool for individuals at elevated risk of fatty liver disease and cardiometabolic comorbidities. Further prospective studies are warranted to clarify causality and clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/home<\/jats:ext-link>\n                      , identifier CRD42025116919.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1800577","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:15:20Z","timestamp":1774930520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between the atherogenic index of plasma and metabolic-associated\/nonalcoholic fatty liver disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yanxin","family":"Zhao","sequence":"first","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshan","family":"Huang","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlang","family":"Ren","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Lu","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejia","family":"Xiong","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqing","family":"Ma","sequence":"additional","affiliation":[{"name":"Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1509232","article-title":"Global, regional, and national burden of NAFLD in youths and young adults aged 15-39 years, 1990-2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021","volume":"12","author":"Wang","year":"2025","journal-title":"Front Nutr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111652","article-title":"Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population","volume":"211","author":"Chew","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-023-01886-5","article-title":"Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study","volume":"22","author":"Yin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20240991","article-title":"Associations of the atherogenic index of plasma with insulin resistance and inflammation","volume":"70","author":"Altun","year":"2024","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1140215","article-title":"The atherogenic index of plasma (AIP) is a predictor for the severity of coronary artery disease","volume":"10","author":"Li","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12933-025-02941-z","article-title":"Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based on NHANES 1999-2018","volume":"24","author":"Gan","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.20074","article-title":"Diagnostic accuracy of the atherogenic index of plasma in metabolic syndrome: a diagnostic meta-analysis","volume":"13","author":"Gao","year":"2025","journal-title":"PeerJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/medicina61040611","article-title":"Atherogenic index of plasma in metabolic syndrome-a systematic review and meta-analysis","volume":"61","author":"Andraschko","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12944-019-1112-6","article-title":"Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in the Chinese Han population","volume":"18","author":"Xie","year":"2019","journal-title":"Lipids Health Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2025.09.1106","article-title":"Comparative analysis of metabolic and inflammatory biomarker profiles in phenotypes of metabolic dysfunction-associated fatty liver disease","volume":"35","author":"Nida","year":"2025","journal-title":"J Coll Phys Surg Pak"},{"key":"B15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-025-02716-6","article-title":"Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study","volume":"24","author":"Song","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i36.5364","article-title":"Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease","volume":"28","author":"Duan","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1038\/s41598-025-93141-y","article-title":"Atherogenic index of plasma identifies subjects with severe liver steatosis","volume":"15","author":"De Matteis","year":"2025","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40001-022-00731-x","article-title":"Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes","volume":"27","author":"Samimi","year":"2022","journal-title":"Eur J Med Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/190867","article-title":"Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index","volume":"21","author":"Ciftel","year":"2025","journal-title":"Arch Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1405828","article-title":"Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/diagnostics12102426","article-title":"A study of biomarkers associated with metabolic dysfunction-associated fatty liver disease in patients with type 2 diabetes","volume":"12","author":"Efrem","year":"2022","journal-title":"Diagn (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12944-021-01560-3","article-title":"Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China","volume":"20","author":"Xie","year":"2021","journal-title":"Lipids Health Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S375300","article-title":"A cross-sectional study of the correlation between the atherogenic index of plasma and nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"15","author":"Lin","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01808-0","article-title":"Development and validation of an online dynamic nomogram based on the atherogenic index of plasma to screen nonalcoholic fatty liver disease","volume":"22","author":"Peng","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/dmso.S441641","article-title":"Predictors of high cardiovascular risk among nonobese patients with type 2 diabetes and non-alcoholic fatty liver disease in a Chinese population","volume":"17","author":"Ruan","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2025.46.5.20240901","article-title":"The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia","volume":"46","author":"Mohammedsaeed","year":"2025","journal-title":"Saudi Med J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1511952","article-title":"Association between the atherogenic index of plasma and non-alcoholic fatty liver disease in Korean pregnant women: secondary analysis of a prospective cohort study","volume":"12","author":"Shuai","year":"2025","journal-title":"Front Nutr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13813455.2018.1429475","article-title":"Association of carotid intima media thickness with atherogenic index of plasma, apo B\/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease","volume":"125","author":"Fadaei","year":"2019","journal-title":"Arch Physiol Biochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/lipd.12453","article-title":"Associations between novel lipid indicators and the risk of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"60","author":"Wang","year":"2025","journal-title":"Lipids"},{"key":"B30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12944-018-0932-0","article-title":"Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study","volume":"17","author":"Wang","year":"2018","journal-title":"Lipids Health Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.954219","article-title":"The atherogenic index of plasma: a novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults","volume":"9","author":"Liu","year":"2022","journal-title":"Front Nutr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12944-020-01319-2","article-title":"The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study","volume":"19","author":"Dong","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/biomedicines10092101","article-title":"Atherogenic index of plasma in non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"10","author":"Ismaiel","year":"2022","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1607601","article-title":"The association of the atherogenic index of plasma with hypertension, diabetes, and their comorbidities in Chinese middle-aged and elderly people: a cross-sectional study from CHARLS","volume":"12","author":"Zhou","year":"2025","journal-title":"Front Nutr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2561229","article-title":"Associations of triglyceride glucose index and atherogenic index of plasma with plaque, inflammation, flow, and functional ischemia assessed by cardiovascular computed tomography imaging in hypertensive patients: a study of different glucose metabolism status","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.3390\/ijms26146962","article-title":"Lipid accumulation and insulin resistance: bridging metabolic dysfunction-associated fatty liver disease and chronic kidney disease","volume":"26","author":"Cao","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156392","article-title":"27-hydroxycholesterol exacerbates hepatic insulin resistance via plasma membrane cholesterol remodeling","volume":"173","author":"Yang","year":"2025","journal-title":"Metabolism"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.01.026","article-title":"Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance","volume":"1863","author":"Qiu","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/life15111713","article-title":"Crosstalk between metabolic dysfunction-associated steatotic liver disease and atrial fibrillation: shared mechanism, diagnostic integration, and management implications","volume":"15","author":"Morawska","year":"2025","journal-title":"Life (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jare.2024.03.004","article-title":"Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: a review","volume":"68","author":"Li","year":"2025","journal-title":"J Adv Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.26599\/FMH.2025.9420056","article-title":"Role of selenium and 17\u03b2 oestradiol in modulating lipid accumulation in in vitro models of obesity and NAFLD","volume":"2","author":"Walsh","year":"2025","journal-title":"Food Med Homol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.76","article-title":"Decoding the role of immune T cells: a new territory for improvement of metabolic-associated fatty liver disease","volume":"2","author":"Liu","year":"2023","journal-title":"Imeta"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.26599\/FMH.2026.9420081","article-title":"Goji-derived exosomes-like nanoparticles ameliorate alcohol-induced acute liver injury by modulating gut microbiota and metabolites","volume":"3","author":"Guo","year":"2026","journal-title":"Food Med Homol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.61","article-title":"Targeting keystone species helps restore the dysbiosis of butyrate-producing bacteria in nonalcoholic fatty liver disease","volume":"1","author":"Wu","year":"2022","journal-title":"Imeta"},{"key":"B47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13098-025-01800-x","article-title":"Prognostic value of atherogenic index of plasma on the all-cause and causes-specific mortality among patients with metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Song","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10157-y","article-title":"Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD","volume":"15","author":"Guerreiro","year":"2021","journal-title":"Hepatol Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"40680","DOI":"10.1038\/s41598-025-21073-8","article-title":"Association between triglyceride glucose index-related indices with gallbladder disease: a prospective cohort study in rural China","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1800577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:15:22Z","timestamp":1774930522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1800577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":49,"alternative-id":["10.3389\/fendo.2026.1800577"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1800577","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1800577"}}